Form 4: ACM Research CFO Exercises Options and Sells Shares Under 10b5-1 Plan

Mark McKechnie, CFO of ACM Research, exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 12, 2025, Mark McKechnie, the CFO and Treasurer of ACM Research, exercised stock options to acquire 15,000 shares of Class A Common Stock at a price of $5.60 per share.
• Concurrently, McKechnie sold 15,000 shares of Class A Common Stock at a weighted average price of $27.42, with individual sales ranging from $27.05 to $27.91.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 7, 2024.
• Following these transactions, McKechnie directly owns 900 shares of Class A Common Stock and 15,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports routine transactions under a pre-existing trading plan. There's no indication of positive or negative implications for the company's outlook.

Future Outlook

NA

Industry Context

This filing reflects routine insider transactions under a pre-arranged trading plan, which is a common practice among corporate executives to avoid accusations of trading on non-public information. It's important to monitor such filings in conjunction with overall company performance and industry trends to assess the potential impact on investor sentiment.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among executives at publicly traded companies, including those in the semiconductor industry like Applied Materials (AMAT) and Lam Research (LRCX).
• The reported weighted average sale price of $27.42 is within the typical range observed for ACM Research's stock, but it's essential to compare it against the prevailing market conditions and analyst expectations at the time of the transaction.
• The size of the transaction, involving 15,000 shares, is relatively modest compared to the overall trading volume of ACMR, suggesting it's unlikely to have a significant impact on the stock price.

Key Dates